-
Something wrong with this record ?
Toward clinically applicable biomarkers for asthma: An EAACI position paper
Z. Diamant, S. Vijverberg, K. Alving, A. Bakirtas, L. Bjermer, A. Custovic, SE. Dahlen, M. Gaga, R. Gerth van Wijk, SD. Giacco, E. Hamelmann, LG. Heaney, E. Heffler, Ö. Kalayci, K. Kostikas, R. Lutter, AC. Olin, S. Sergejeva, A. Simpson, PJ....
Language English Country Denmark
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
EAACI:Task Force grant - International
PubMed
30953574
DOI
10.1111/all.13806
Knihovny.cz E-resources
- MeSH
- Biomarkers * MeSH
- Asthma diagnosis etiology therapy MeSH
- Molecular Targeted Therapy MeSH
- Cytokines metabolism MeSH
- Respiratory System immunology metabolism pathology MeSH
- Phenotype MeSH
- Combined Modality Therapy MeSH
- Critical Pathways * MeSH
- Humans MeSH
- Disease Management MeSH
- Inflammation Mediators metabolism MeSH
- Disease Susceptibility MeSH
- Airway Remodeling MeSH
- T-Lymphocyte Subsets immunology metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Inflammation, structural, and functional abnormalities within the airways are key features of asthma. Although these processes are well documented, their expression varies across the heterogeneous spectrum of asthma. Type 2 inflammatory responses are characterized by increased levels of eosinophils, FeNO, and type 2 cytokines in blood and/or airways. Presently, type 2 asthma is the best-defined endotype, typically found in patients with allergic asthma, but surprisingly also in nonallergic patients with (severe) asthma. The etiology of asthma with non-type 2 inflammation is less clear. During the past decade, targeted therapies, including biologicals and small molecules, have been increasingly integrated into treatment strategies of severe asthma. These treatments block specific inflammatory pathways or single mediators. Single or composite biomarkers help to identify patients who will benefit from these treatments. So far, only a few inflammatory biomarkers have been validated for clinical application. The European Academy of Allergy & Clinical Immunology Task Force on Biomarkers in Asthma was initiated to review different biomarker sampling methods and to investigate clinical applicability of new and existing inflammatory biomarkers (point-of-care) to support diagnosis, targeted treatment, and monitoring of severe asthma. Subsequently, we discuss existing and novel targeted therapies for asthma as well as applicable biomarkers.
7th Respiratory Medicine Department and Asthma Centre Athens Chest Hospital Athens Greece
Department of Clinical Pharmacy and Pharmacology UMCG and QPS NL Groningen The Netherlands
Department of Medical Sciences and Public Health University of Cagliari Cagliari Italy
Department of Respiratory Medicine Amsterdam UMC University of Amsterdam Amsterdam The Netherlands
Department of Women's and Children's Health Uppsala University Uppsala Sweden
Division of Pediatric Allergy Faculty of Medicine Hacettepe University Ankara Turkey
Institute of Technology University of Tartu Tartu Estonia
Respiratory Medicine Department University of Ioannina Medical School Ioannina Greece
Section of Paediatrics Department of Medicine Imperial College London London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025593
- 003
- CZ-PrNML
- 005
- 20201222160307.0
- 007
- ta
- 008
- 201125s2019 dk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/all.13806 $2 doi
- 035 __
- $a (PubMed)30953574
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a dk
- 100 1_
- $a Diamant, Zuzana $u Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden. Department of Clinical Pharmacy and Pharmacology, UMCG and QPS-NL, Groningen, The Netherlands. Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
- 245 10
- $a Toward clinically applicable biomarkers for asthma: An EAACI position paper / $c Z. Diamant, S. Vijverberg, K. Alving, A. Bakirtas, L. Bjermer, A. Custovic, SE. Dahlen, M. Gaga, R. Gerth van Wijk, SD. Giacco, E. Hamelmann, LG. Heaney, E. Heffler, Ö. Kalayci, K. Kostikas, R. Lutter, AC. Olin, S. Sergejeva, A. Simpson, PJ. Sterk, E. Tufvesson, I. Agache, SF. Seys,
- 520 9_
- $a Inflammation, structural, and functional abnormalities within the airways are key features of asthma. Although these processes are well documented, their expression varies across the heterogeneous spectrum of asthma. Type 2 inflammatory responses are characterized by increased levels of eosinophils, FeNO, and type 2 cytokines in blood and/or airways. Presently, type 2 asthma is the best-defined endotype, typically found in patients with allergic asthma, but surprisingly also in nonallergic patients with (severe) asthma. The etiology of asthma with non-type 2 inflammation is less clear. During the past decade, targeted therapies, including biologicals and small molecules, have been increasingly integrated into treatment strategies of severe asthma. These treatments block specific inflammatory pathways or single mediators. Single or composite biomarkers help to identify patients who will benefit from these treatments. So far, only a few inflammatory biomarkers have been validated for clinical application. The European Academy of Allergy & Clinical Immunology Task Force on Biomarkers in Asthma was initiated to review different biomarker sampling methods and to investigate clinical applicability of new and existing inflammatory biomarkers (point-of-care) to support diagnosis, targeted treatment, and monitoring of severe asthma. Subsequently, we discuss existing and novel targeted therapies for asthma as well as applicable biomarkers.
- 650 _2
- $a remodelace dýchacích cest $7 D056151
- 650 _2
- $a bronchiální astma $x diagnóza $x etiologie $x terapie $7 D001249
- 650 12
- $a biologické markery $7 D015415
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 12
- $a kritické cesty $7 D019091
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a náchylnost k nemoci $7 D004198
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mediátory zánětu $x metabolismus $7 D018836
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a dýchací soustava $x imunologie $x metabolismus $x patologie $7 D012137
- 650 _2
- $a T-lymfocyty - podskupiny $x imunologie $x metabolismus $7 D016176
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vijverberg, Susanne $u Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Alving, Kjell $u Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
- 700 1_
- $a Bakirtas, Arzu $u Department of Pediatrics, Division of Pediatric Allergy and Asthma, Gazi University School of Medicine, Ankara, Turkey.
- 700 1_
- $a Bjermer, Leif $u Department of Clinical Pharmacy and Pharmacology, UMCG and QPS-NL, Groningen, The Netherlands.
- 700 1_
- $a Custovic, Adnan $u Section of Paediatrics, Department of Medicine, Imperial College London, London, UK.
- 700 1_
- $a Dahlen, Sven-Erik $u Experimental Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Gaga, Mina $u 7th Respiratory Medicine Department and Asthma Centre, Athens Chest Hospital, Athens, Greece.
- 700 1_
- $a Gerth van Wijk, Roy $u Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
- 700 1_
- $a Giacco, Stefano Del $u Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
- 700 1_
- $a Hamelmann, Eckard $u Children's Center, Protestant Hospital Bethel, Bielefeld, Germany. Allergy Center, Ruhr University Bochum, Bochum, Germany.
- 700 1_
- $a Heaney, Liam G $u Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
- 700 1_
- $a Heffler, Enrico $u Department of Biomedical Sciences, Humanitas University, Milan, Italy. Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Milan, Italy.
- 700 1_
- $a Kalayci, Ömer $u Division of Pediatric Allergy, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
- 700 1_
- $a Kostikas, Konstantinos $u Respiratory Medicine Department, University of Ioannina Medical School, Ioannina, Greece.
- 700 1_
- $a Lutter, Rene $u Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Olin, Anna-Carin $u Section of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- 700 1_
- $a Sergejeva, Svetlana $u Institute of Technology, University of Tartu, Tartu, Estonia.
- 700 1_
- $a Simpson, Angela $u Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, University of Manchester and University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
- 700 1_
- $a Sterk, Peter J $u Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Tufvesson, Ellen $u Department of Clinical Pharmacy and Pharmacology, UMCG and QPS-NL, Groningen, The Netherlands.
- 700 1_
- $a Agache, Ioana $u Department of Allergy and Clinical Immunology, Faculty of Medicine, Transylvania University Brasov, Brasov, Romania.
- 700 1_
- $a Seys, Sven F $u Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- 773 0_
- $w MED00009088 $t Allergy $x 1398-9995 $g Roč. 74, č. 10 (2019), s. 1835-1851
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30953574 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222160303 $b ABA008
- 999 __
- $a ok $b bmc $g 1599738 $s 1116279
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 74 $c 10 $d 1835-1851 $e - $i 1398-9995 $m Allergy $n Allergy $x MED00009088
- GRA __
- $p EAACI:Task Force grant $2 International
- LZP __
- $a Pubmed-20201125
